We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Swiss miss

31 Jan 2006 By Robert Cyran

The Swiss biotech has attracted no bidders at $15bn. This worsens the dilemma of Bertarelli, the boss and controlling shareholder. If he really wants out, the price must be cut. But doing so smacks of desperation and could put even a fair price out of reach.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)